How much does the boss earn - CEO pay at CROs

By Nick Taylor

- Last updated on GMT

Related tags Income U.s. securities and exchange commission Ceo

How much does the boss earn - CEO pay at CROs
Outsourcing-Pharma views the wages of CEOs at six major CROs using interactive charts to explore their basic salary, incentives and how much they get paid compared to company revenues.

CEOs at contract research organisations (CRO) earn millions of dollars a year and the reasoning behind this, and differences between companies, is detailed below.

There was some variation in the basic salaries of the six CEOs in 2008, as shown in the chart below. Josef von Rickenbach of Parexel had the smallest basic salary, earning $550,000 (€379,000), and James Foster had the biggest, earning $950,000.

Basic salaries are based on a combination of factors, with the CROs considering what their peers are paying executives, the experience of the individual and how long they have been at the company.

The difference in wages becomes more pronounced when the total pay is looked at. These figures include bonuses, stock awards and other compensation that can significantly increase CEOs’ earnings.

For instance, the extras increased the basic salary of Joseph Herring, CEO of Covance, by 641 per cent resulting in total earnings of $5.41m. Foster’s basic salary rose by 579 per cent and other CEOs had smaller but still significant earnings.

This is shown on the chart below. Candace Kendle, CEO of Kendle, had the smallest extras payments, which increased her basic salary by 33 per cent.

Variable, performance based payments are regarded by the CROs as an important aspect of operations, with Charles River describing stock incentives as an important technique to “attract, motivate and retain key employees and directors​”.

The incentive payments are made based on the achievement of financial and non-financial goals. Below is a chart showing how many US dollars each CEO earned for every $1000 of revenue the company generated.

 

All figures are taken from companies​' regulatory filings with the US Securities and Exchange Commission.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers

Follow us

Products

View more

Webinars